Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: Follow-up of the CoBalT randomised controlled trial

The Lancet Psychiatry

Volumn 3, Issue 2, 2016, Pages 137-144

  Wiles, Nicola J ^a   Thomas, Laura ^a   Turner, Nicholas ^a   Garfield, Kirsty ^a   Kounali, Daphne ^a   Campbell, John ^c   Kessler, David ^a   Kuyken, Willem ^d   Lewis, Glyn ^e   Morrison, Jill ^f   Williams, Chris ^g   Peters, Tim J ^b   Hollinghurst, Sandra ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; COGNITIVE THERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HUMAN; ICD-10; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT RESISTANT DEPRESSION; ADOLESCENT; COST BENEFIT ANALYSIS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; ECONOMICS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRIMARY HEALTH CARE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957426606     PISSN: 22150366     EISSN: 22150374     Source Type: Journal    
DOI: 10.1016/S2215-0366(15)00495-2     Document Type: Article

References (41)

1. Butler AC, Chapman JE, Forman EM, Beck AT The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 2006, 26:17-31.
2. DeRubeis RJ, Hollon SD, Amsterdam JD, et al. Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 2005, 62:409-416.
3. Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet 2013, 381:375-384.
4. Miller IW, Norman WH, Keitner GI Cognitive-behavioural treatment of depressed inpatients: six- and twelve- month follow-up. Am J Psychiatry 1989, 146:1274-1279.
5. Kovacs M, Rush AJ, Beck AT, Hollon SD Depressed outpatients treated with cognitive therapy or pharmacotherapy. Arch Gen Psychiatry 1981, 38:33-39.
6. Simons AD, Murphy GE, Levine JL, Wetzel RD Cognitive therapy and pharmacotherapy for depression. Arch Gen Psychiatry 1986, 43:43-48.
7. Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005, 62:417-422.
8. Kessler D, Lewis G, Kaur S, et al. Therapist-delivered internet psychotherapy for depression in primary care: a randomised controlled trial. Lancet 2009, 374:628-634.
9. Hollinghurst S, Peters TJ, Kaur S, Wiles N, Lewis G Cost-effectiveness of therapist-delivered online cognitive-behavioural therapy for depression: randomised controlled trial. Br J Psychiatry 2010, 197:297-304.
10. Hollinghurst S, Carroll FE, Abel A, et al. Cost-effectiveness of cognitive-behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: economic evaluation of the CoBalT Trial. Br J Psychiatry 2014, 204:69-76.
11. Fava GA, Grandi S, Zielezny M, Rafanelli C, Canestrari R Four-year outcome for cognitive behavioural treatment of residual symptoms in major depression. Am J Psychiatry 1996, 153:945-947.
12. Fava GA, Rafanelli C, Grandi S, Canestrari R, Morphy MA Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998, 155:1443-1445.
13. Paykel ES, Scott J, Cornwall PL, et al. Duration of relapse prevention after cognitive therapy in residual depression: follow-up of controlled trial. Psychol Med 2005, 35:59-68.
14. Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999, 56:829-835.
15. Wang PS, Simon G, Kessler RC The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003, 12:22-33.
16. Olchanski N, McInnis Myers M, Halseth M, et al. The economic burden of treatment-resistant depression. Clin Ther 2013, 35:512-522.
17. Durham RC, Chambers JA, Power KG, et al. Long-term outcome of cognitive behaviour therapy clinical trials in central Scotland. Health Technol Assess 2005, 9:1-174.
18. Talking therapies: a four-year plan of action 2011, Department of Health, Department of Health, London.
19. Thomas L, Kessler D, Campbell J, et al. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br J Gen Pract 2013, 63:e852-e858.
20. Thomas LJ, Abel A, Ridgway N, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: the CoBalT randomised controlled trial protocol. Control Clin Trials 2012, 33:312-319.
21. Beck AT, Steer RA, Brown GK Beck Depression Inventory-second edition: manual 1996, The Psychological Corporation, San Antonio.
22. Blackburn IM, James IA, Milne DL, et al. The revised cognitive therapy scale (CTS-R): psychometric properties. Behav Cogn Psychother 2001, 29:431-446.
23. Jenkinson C, Layte R Development and testing of the UK SF-12 (short form health survey). J Health Serv Res Pol 1997, 2:14-18.
24. Kroenke K, Spitzer RL, Williams JB The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16:606-613.
25. Spitzer RL, Kroenke K, Williams JBW, Lowe B A brief measure for assessing generalized anxiety disorder. The GAD-7. Arch Intern Med 2006, 166:1092-1097.
26. van Hout B, Janssen MF, You-Shan F, et al. Interim Scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. ValueHealth 2012, 15:708-715.
27. Shults J, Ratcliffe SJ, Leonard M Improved generalized estimating equation analysis via xtqls for quasi-least squares in Stata. Stata J 2007, 7:147-166.
28. van Buuren S, Boshuizen HC, Knook DL Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999, 18:681-694.
29. Molenberghs G, Kenward MG Missing data in clinical studies 2007, John Wiley & Sons, Chichester.
30. Diggle P Dealing with missing values in longitudinal studies. Statistical analysis of medical data: new developments 1998, 203-227. Arnold, London. D.E. Everitt, G. Dunn (Eds.).
31. Diggle P An approach to the analysis of repeated measurements. Biometrics 1998, 44:959-971.
32. Curtis L Unit costs of health and social care 2013 2013, PSSRU, University of Kent, Canterbury.
33. NHS Reference Costs 2013, Department of Health, Department of Health, London.
34. Prescription cost analysis England 2013 2014, Health & Social Care Information Centre, Health and Social Care Information Centre, London.
35. Guide to the Methods of Technology Appraisal 2008, National Institute for Health and Clinical Excellence, Department of Health, London.
36. Trivedi RB, Nieuwsma JA, Williams JW Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. J Gen Intern Med 2011, 26:643-650.
37. Perez-Wehbe AI, Perestelo-Perez L, Bethencourt-Perez JM, Cuellar-Pompa L, Penate-Castro W Treatment-resistant depression: A systematic review of systematic reviews. Intern J Clin Health Psychol 2014, 14:145-155.
38. Driessen E, Van HL, Don FJ, et al. The efficacy of cognitive-behavioral therapy and psychodynamic therapy in the outpatient treatment of major depression: a randomized clinical trial. Am J Psychiatry 2013, 170:1041-1050.
39. Fostick L, Silberman A, Beckman M, Spivak B, Amital D The economic impact of depression: resistance or severity?. Eur Neuropsychopharmacol 2010, 20:671-675.
40. Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care 2010, 16:370-377.
41. Psychological therapies, annual report on the use of IAPT services: England-2013/14 experimental statistics 2014, Health and Social Care Information Centre, Health and Social Care Information Centre, London.